drugset / Trial / NCT05184517
A Feasibility Study to Evaluate the Tolerability of Oph1 Compared to Restasis in Healthy Volunteers
RandomizedCrossoverDouble-blindOther
Summary
20 healthy participants will be evaluated for tolerability and safety of a new eye drop formulation for treatment of Dry Eye Syndromes, Oph1 0.5% Cyclosporine A (CsA) compared with Restasis 0.05% CsA ophthalmic formulation.
Timeline
- Start
- 2023-01-23
- Primary completion
- 2023-07-06
- Completion
- 2023-09-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oph1 | Unknown | 0.05 % | Other |
| Subject | Oph1 | Unknown | 0.5 % | Other |